Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 4/20 | 0.61 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | FNTA | P49354 | 6/20 | 0.47 |
| ▸ | FNTB | P49356 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28346014 | 1.00 | GABBR2 (0.61) | GABBR2GABBR1MAPTFNTAFNTB | |
| SCHEMBL2289954 | 0.89 | GABBR2 (0.58) | GABBR2GABBR1MAPTFNTAFNTB | |
| SCHEMBL28642990 | 0.89 | GABBR2 (0.47) | GABBR2GABBR1MAPTPOLBLMNA | |
| SCHEMBL7663044 | 0.87 | GABBR2 (0.56) | GABBR2GABBR1MAPTPOLB | |
| SCHEMBL4403980 | 0.86 | GABBR2 (0.54) | GABBR2GABBR1MAPT | |
| SCHEMBL3242852 | 0.86 | GABBR2 (0.54) | GABBR2GABBR1MAPT | |
| SCHEMBL27688433 | 0.86 | GABBR2 (0.54) | GABBR2GABBR1MAPT | |
| SCHEMBL184884 | 0.85 | ALDH1A1 (0.54) | GABBR2GABBR1MAPTPOLBLMNA | |
| SCHEMBL15614666 | 0.85 | ALDH1A1 (0.54) | GABBR2GABBR1MAPTPOLBLMNA | |
| SCHEMBL3879432 | 0.85 | ESR1 (0.59) | GABBR2GABBR1MAPTFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173227-A1 | A FRAGRANCE MIXTURE CONTAINING ISOCITRONELLOL | SYMRISE AG (DE) | 2024-05-30 | — | — | US | claimed |
| WO-2009131692-A1 | SUBSTRATES FOR DELIVERY OF PHYSIOLOGICALLY ACTIVE AGENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2009-10-29 | — | — | WO | claimed |
| EP-0244167-B1 | IMPROVED PROCESS FOR PREPARING POLY (ARYL ETHERS) AND POLY (ARYL ETHER KETONES) | AMOCO CORPORATION (US) | 1990-04-04 | — | — | EP | claimed |
| CN-119875109-A | Low-odor hydrolysis-resistant mercaptan curing agent and preparation method and application thereof | 益丰新材料股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-110590552-B | Synthetic method of acetate compound | 青岛农业大学 | 2022-02-08 | — | — | CN | disclosed |
| CN-110590552-A | Synthetic method of acetate compound | 青岛农业大学 | 2019-12-20 | — | — | CN | disclosed |
| US-9371296-B2 | Bicyclic 1,3,4-oxadiazole derivatives as sphingosine-1-phosphate receptors' modulators | ALLERGAN, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160137616-A1 | BICYCLIC 1,3,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTORS' MODULATORS | ALLERGAN, INC. | 2016-05-19 | — | — | US | disclosed |
| WO-2015134467-A1 | METHODS AND COMPOSITIONS FOR DIRECT RADIOACTIVE LABELING OF BIO-ACTIVE MOLECULES AND BUILDING BLOCKS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015108577-A1 | DIPHENYL UREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| US-8304223-B2 | Isoforms of pig liver esterase | ENZYMICALS AG (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-7229817-B2 | Recombinant porcine liver esterases, their use and a method for the production thereof | DEGUSSA AG (DE) | 2007-06-12 | — | — | US | disclosed |
| CN-1806206-A | Photosensitive resin composition | AZ ELECTRONIC MATERIALS JAPAN (JP) | 2006-07-19 | — | — | CN | disclosed |
| EP-0738269-B1 | PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | URIACH & CIA SA J (ES) | 2000-04-26 | — | — | EP | disclosed |
| US-5705504-A | PLATELET ACTIVATING FACTOR | J. URIACH & CIA, S.A. (ES) | 1998-01-06 | — | — | US | disclosed |
| US-4537871-A | Carbonylation catalyst | THE HALCON SD GROUP, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| US-4483803-A | Preparation of carboxylic acid anhydrides | THE HALCON SD GROUP, INC. (US) | 1984-11-20 | — | — | US | disclosed |
| US-4335058-A | Preparation of carboxylic acid anhydrides | HALCON RESEARCH AND DEVELOPMENT CORP. (US) | 1982-06-15 | — | — | US | disclosed |
| US-4273873-A | BONDING SYNTHETIC FIBRINOLYTIC COMPOUND OR ENZYME | UNITIKA LTD. (JP) | 1981-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | GABBR2 993/4885GABBR1 746/4885MAPT 1444/4885 |
| US-20160137616-A1 | BICYCLIC 1,3,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTORS' MODULATORS | S1PR3, S1PR1, S1PR4 | GABBR2 537/4885GABBR1 495/4885MAPT 3562/4885 |
| US-20240173227-A1 | A FRAGRANCE MIXTURE CONTAINING ISOCITRONELLOL | IPO5, OR51E2, FDFT1 | GABBR2 2842/4885GABBR1 2773/4885MAPT 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.